$0
Thoughts on Gilead’s Acquisition of Tmunity
On Tuesday, December 20, 2022, Gilead (Kite) announced (press release) the acquisition of Tmunity Therapeutics. As part of the transaction, Gilead will continue Tmunity’s strategic research and licensing agreement with UPenn. Below, Celltelligence provides insights on the acquisition, while discussing Gilead’s potential strategy when it comes to solid tumors.